Optimvia is a biopharmaceutical company that leverages its proprietary ADEPT® Platform to engineer enzymes and their cofactors for the synthesis of complex therapeutic molecules, with a primary focus on biosynthetic heparin. This innovative platform allows Optimvia to replicate the natural synthesis of heparin, a critical anticoagulant, by creating new enzymes and cofactors. The company aims to address the limitations of traditional heparin production, which relies on animal sources, by developing a scalable and commercially viable manufacturing process that not only replaces animal-derived heparin but also enables the creation of novel designer heparin-like pharmaceuticals with enhanced properties.

In addition to its core technology, Optimvia has formed a strategic partnership with Ginkgo Bioworks, a leader in cell programming, to enhance the manufacturing efficiency of its biosynthetic heparin technology. This collaboration is aimed at scaling production to meet global demand while eliminating the need for animal sources entirely. Through these advancements, Optimvia is positioned to transform the landscape of heparin production and contribute significantly to therapeutic innovations in areas such as anti-coagulation and cancer treatment.

United States

Optimvia is a biopharmaceutical company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules. The company leverages its ADEPT™ platform to engineer biosynthetic heparin and aims to manufacture non-animal derived heparin as proof of principle for its platform.

Optimvia

Company Details